JP2025532676A - 痙縮治療のためのｎｇｆ - Google Patents

痙縮治療のためのｎｇｆ

Info

Publication number
JP2025532676A
JP2025532676A JP2025517344A JP2025517344A JP2025532676A JP 2025532676 A JP2025532676 A JP 2025532676A JP 2025517344 A JP2025517344 A JP 2025517344A JP 2025517344 A JP2025517344 A JP 2025517344A JP 2025532676 A JP2025532676 A JP 2025532676A
Authority
JP
Japan
Prior art keywords
ngf
mutant protein
seq
tbi
spasticity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025517344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025532676A5 (cg-RX-API-DMAC10.html
Inventor
アレグレッティ，マルチェッロ
アラミニ，アンドレア
ブランドリーニ，ローラ
カッターニ，フランカ
マンテルリ，フラビオ
Original Assignee
ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ filed Critical ドムペ・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ
Publication of JP2025532676A publication Critical patent/JP2025532676A/ja
Publication of JP2025532676A5 publication Critical patent/JP2025532676A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2025517344A 2022-09-23 2023-09-25 痙縮治療のためのｎｇｆ Pending JP2025532676A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22197562.6 2022-09-23
EP22197562.6A EP4342485A1 (en) 2022-09-23 2022-09-23 Ngf for the treatment of spasticity
PCT/EP2023/076387 WO2024062135A1 (en) 2022-09-23 2023-09-25 Ngf for the treatment of spasticity

Publications (2)

Publication Number Publication Date
JP2025532676A true JP2025532676A (ja) 2025-10-01
JP2025532676A5 JP2025532676A5 (cg-RX-API-DMAC10.html) 2026-04-28

Family

ID=83438536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025517344A Pending JP2025532676A (ja) 2022-09-23 2023-09-25 痙縮治療のためのｎｇｆ

Country Status (10)

Country Link
EP (3) EP4342485A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025532676A (cg-RX-API-DMAC10.html)
CN (1) CN120239610A (cg-RX-API-DMAC10.html)
AU (1) AU2023345675A1 (cg-RX-API-DMAC10.html)
CA (1) CA3266315A1 (cg-RX-API-DMAC10.html)
DK (1) DK4590324T3 (cg-RX-API-DMAC10.html)
FI (1) FI4590324T3 (cg-RX-API-DMAC10.html)
IL (1) IL319010A (cg-RX-API-DMAC10.html)
PT (1) PT4590324T (cg-RX-API-DMAC10.html)
WO (1) WO2024062135A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4623927A1 (en) 2024-03-27 2025-10-01 Dompe' Farmaceutici SpA Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy
WO2026022244A1 (en) 2024-07-23 2026-01-29 Chiesi Farmaceutici S.P.A. A polypeptide for use in the therapeutic management of acute ischaemic stroke
US20260166124A1 (en) * 2024-12-17 2026-06-18 Dompe` farmaceutici S.P.A. Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders
EP4763217A1 (en) * 2024-12-17 2026-06-24 Dompé farmaceutici SpA Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257514T1 (de) 1998-10-09 2004-01-15 Scil Proteins Gmbh Verfahren zur gewinnung von aktivem beta-ngf
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
ES2545701T3 (es) 2011-12-19 2015-09-15 Wacker Chemie Ag Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF
CN109071678B (zh) * 2016-03-18 2022-05-20 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
IT201600112420A1 (it) * 2016-11-08 2018-05-08 Univ Cattolica Del Sacro Cuore Nuova formulazione per via intranasale
WO2019207106A1 (en) 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
AU2020347812B2 (en) * 2019-09-17 2026-05-28 Chiesi Farmaceutici S.P.A. Agent for use in treatment or prevention of ophthalmic disorders
WO2022105847A1 (en) * 2020-11-19 2022-05-27 Staidson (Beijing) Biopharmaceuticals Co. , Ltd. Long-acting nerve growth factor polypeptides and uses thereof

Also Published As

Publication number Publication date
EP4772196A3 (en) 2026-08-19
DK4590324T3 (en) 2026-07-20
CA3266315A1 (en) 2024-03-28
EP4342485A1 (en) 2024-03-27
EP4590324B1 (en) 2026-06-24
EP4590324A1 (en) 2025-07-30
WO2024062135A1 (en) 2024-03-28
FI4590324T3 (fi) 2026-07-29
IL319010A (en) 2025-04-01
PT4590324T (pt) 2026-07-20
CN120239610A (zh) 2025-07-01
EP4772196A2 (en) 2026-07-08
AU2023345675A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
WO2024062135A1 (en) Ngf for the treatment of spasticity
US12503501B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
JP4154237B2 (ja) 異痛症および他の種々のタイプの慢性疼痛または幻肢痛を治療するための化合物のペプチドクラスの新規使用
Zhang et al. Enriched environment promotes post-stroke neurogenesis through NF-κB-mediated secretion of IL-17A from astrocytes
US20180250365A1 (en) Acth for treatment of amyotrophic lateral sclerosis
JP2838073B2 (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
CN112533676A (zh) 用于抑制cgrp的神经毒素
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
EP2640410B1 (de) Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
WO2009049215A1 (en) Methods to reduce the effects of sleep deprivation
Westin et al. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy
Leung et al. Cholinergic modulation of general anesthesia
Huang et al. The macroscopic and microscopic effect of low-frequency whole-body vibration after cerebral ischemia in rats
Morishita et al. Subacute intranasal oxytocin improves neurological recovery after ischemic stroke
US12246058B2 (en) Methods and compositions for treating pain
KR20190142404A (ko) 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
García del Barco et al. Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model
JP2022544028A (ja) レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物
KR20260049790A (ko) 신경 손상 복구 제품의 제조에서의 2가 금속 락테이트의 용도
US10987411B1 (en) Treatment of chronic obstructive pulmonary disease using botulinum toxin
KR20230071072A (ko) 보툴리눔 독소 조성물
US9896488B2 (en) Protamine in treatment of neuronal injuries
KR20080059229A (ko) 정상적 호흡 리듬의 회복을 위한 ｓ-니트로소티올계 조합제약 생성물
Subramanian Restoration of motor and non-motor functions by neurotrophic factors in nonhuman primates with dopamine depletion
Cairns et al. Tooth pulp–and facial hair mechanoreceptor–evoked responses of trigeminal sensory neurons are attenuated during ketamine anesthesia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420